The 2 drugs tracked here made $17.1B of Gilead’s 2025 revenue (58%) and lose US exclusivity by 2036. Since 2023, Gilead has closed 3 acquisitions of $1B or more, worth $15.3B in total.
Bars are each drug's 2025 sales as a share of Gilead’s total revenue ($29.4B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Mar 2024 | CymaBay TherapeuticsGilead, March 2024 | $4.3B | Other | Seladelpar (now Livdelzi) for the liver disease PBC, approved by the FDA in August 2024, after the deal closedGilead does not report Livdelzi sales separately. | Pipeline only |
| Apr 2026 | ArcellxGilead, April 2026 | $7.8B | Oncology | Full ownership of anito-cel, a CAR-T therapy for multiple myeloma it already co-developedGilead's reported value, including a CVR of $5 per share. | Pipeline only |
| May 2026 | TubulisGilead, May 2026 | $3.15B | Oncology | TUB-040, an antibody-drug conjugate in early trials for ovarian cancerUpfront payment; up to $1.85B more in milestones. | Pipeline only |
| 3 counted | $15.3B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Gilead announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Infectious disease | $17.1B | – |
| Oncology | – | $11.0B |
| Other | – | $4.3B |
Gilead has the most revenue at risk in infectious disease, but has spent the most on acquisitions in oncology. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Gilead paid, not the sales it will bring in. None of the companies it bought had an approved product at closing, so any sales from them are years away and may never arrive. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Settlements with Lupin, Cipla and Laurus Labs bar generics before 1 April 2036, more than two years after Gilead's previous December 2033 estimate. Fierce Pharma
Revenue: Gilead FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Gilead’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →